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ABSTRACT
Introduction Cardiovascular disease (CVD) is an 
important cause of death in breast cancer survivors. 
Some breast cancer treatments including anthracyclines, 
trastuzumab and radiotherapy can increase the risk of 
CVD, especially for patients with pre-existing CVD risk 
factors. Early identification of patients at increased CVD 
risk may allow switching to less cardiotoxic treatments, 
active surveillance or treatment of CVD risk factors. One of 
the strongest independent CVD risk factors is the presence 
and extent of coronary artery calcifications (CAC). In 
clinical practice, CAC are generally quantified on ECG-
triggered cardiac CT scans. Patients with breast cancer 
treated with radiotherapy routinely undergo radiotherapy 
planning CT scans of the chest, and those scans could 
provide the opportunity to routinely assess CAC before a 
potentially cardiotoxic treatment. The Bragatston study 
aims to investigate the association between calcifications 
in the coronary arteries, aorta and heart valves (hereinafter 
called ‘cardiovascular calcifications’) measured 
automatically on planning CT scans of patients with breast 
cancer and CVD risk.
Methods and analysis In a first step, we will optimise 
and validate a deep learning algorithm for automated 
quantification of cardiovascular calcifications on 
planning CT scans of patients with breast cancer. 
Then, in a multicentre cohort study (University Medical 
Center Utrecht, Utrecht, Erasmus MC Cancer Institute, 
Rotterdam and Radboudumc, Nijmegen, The Netherlands), 
the association between cardiovascular calcifications 
measured on planning CT scans of patients with breast 
cancer (n≈16 000) and incident (non-)fatal CVD events 
will be evaluated. To assess the added predictive value of 
these calcifications over traditional CVD risk factors and 
treatment characteristics, a case-cohort analysis will be 
performed among all cohort members diagnosed with a 
CVD event during follow-up (n≈200) and a random sample 
of the baseline cohort (n≈600).
Ethics and dissemination The Institutional Review 
Boards of the participating hospitals decided that the 
Medical Research Involving Human Subjects Act does not 
apply. Findings will be published in peer-reviewed journals 
and presented at conferences.
Trial registration number NCT03206333.
InTRoduCTIon
Over the past 25 years, breast cancer mortality 
rates have declined substantially following 
improvements in therapy and early detec-
tion due to screening.1 2 This, in combina-
tion with high breast cancer incidence rates, 
has resulted in a considerable number of 
breast cancer survivors.3 In 2012, there were 
6.2 million women worldwide who had been 
diagnosed with breast cancer in the previous 
5 years and many of them are assumed to die 
Strengths and limitations of this study
 ► For each patient, an individual cardiovascular risk 
score will be automatically calculated on routine ra-
diotherapy planning CT scans.
 ► Cardiovascular calcifications will be measured using 
an automated deep learning algorithm in an objec-
tive, reproducible and fast manner.
 ► A case-cohort design will be used to estimate ab-
solute risks, which will facilitate clinical (shared) 
decision making.
 ► Outcome data will be obtained through linkage with 
high-quality national registries.
 ► Due to the relatively short follow-up, the number 
of long-term cardiovascular disease events will be 
limited which may lead to an underestimation of the 
prognostic value of cardiovascular calcifications.
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of causes unrelated to breast cancer.3 4 This implies a 
strong need for research on prevention of breast cancer 
treatment-induced complications, such as cardiovascular 
diseases (CVDs).
CVD is the leading cause of death in women worldwide 
accounting for one third of all global female deaths in 
2015.5 Also in patients with breast cancer it is an important 
cause of mortality.4 Colzani et al showed that in patients 
with breast cancer 12% of all deaths within 10 years after 
diagnosis were attributed to CVD, and in the subgroup of 
elderly patients (>65 years) 24% of deaths were CVD-re-
lated.6 Radiotherapy and some systemic therapies such 
as chemotherapy (anthracyclines) and immunotherapy 
(trastuzumab) can increase the risk of CVD, in particular 
in patients with pre-existing CVD risk factors.7–13 Early 
and accurate identification of patients at increased risk 
of CVD, i.e. before breast cancer treatment is adminis-
tered, is important to reduce the burden of CVD in breast 
cancer survivors.
One of the strongest independent CVD risk factors 
is the presence and extent of coronary artery calcifica-
tions (CAC).14 In clinical practice, CAC are quantified 
on ECG-synchronised cardiac CT scans without contrast. 
All patients with breast cancer who receive radiation 
therapy (>60% of patients with breast cancer15) routinely 
undergo a radiotherapy (RT) planning CT scan of the 
chest. Although these scans do not have the same image 
quality for the detection of CAC as cardiac scans due to 
the absence of ECG triggering and lower image resolu-
tion, it has been shown that CAC can still be routinely 
assessed on these scans.16 17 CAC was measured using an 
automated deep learning algorithm which has the advan-
tage of being an objective, reproducible and fast method. 
One in four patients with breast cancer had some degree 
of CAC.16 17 Based on information from RT medical 
records, 28% of patients with severe CAC did not have 
other traditional CVD risk factors.16 However, evidence 
on whether CAC measured on RT planning CT scans is 
a predictor of CVD risk is still lacking. In addition, the 
prognostic value of CAC has not yet been investigated in 
patients with breast cancer.
If patients with breast cancer at increased risk of CVD 
can be identified, these patients may benefit from less 
cardiotoxic treatment strategies, for example, adaptation 
of RT target volumes or technique, chemotherapy dose 
reduction or switching to less harmful regimes, an inter-
vention on CVD risk factors including lifestyle changes or 
pharmacoprevention and from close monitoring for early 
detection of cardiotoxicity during and after breast cancer 
treatment using imaging techniques or biomarkers.18–30 
In that way, the burden of CVD among breast cancer 
survivors could be reduced and lead to a better overall 
survival rate and improved quality of life.
The Bragatston study aims to investigate the association 
between CAC measured automatically on RT planning 
CT scans using a deep learning algorithm and CVD risk 
among patients with breast cancer. Furthermore, thoracic 
aorta calcifications (TAC), aortic valve calcifications 
(AVC) and mitral valve calcifications (MVC) will also be 
analysed as they are also associated with CVD risk.31–33 In 
this manuscript, we report the design of the Bragatston 
study.
METhodS And AnAlySIS
Study aims
The Bragatston study is divided into three work packages 
(WP):
 ► WP 1: this diagnostic package aims to optimise and 
validate an in-house developed automated deep 
learning algorithm to measure the presence and 
extent of CAC, TAC, AVC and MVC (hereinafter 
called ‘cardiovascular calcifications’) on RT planning 
CT scans of patients with breast cancer.
 ► WP 2: this aetiological package will evaluate the asso-
ciation between cardiovascular calcifications meas-
ured automatically on RT planning CT scans and 
the risk of (non-)fatal CVD events in patients with 
breast cancer. It will also evaluate if the association 
is modified by type of (neo-)adjuvant breast cancer 
treatment.
 ► WP 3: this prognostic package will assess the added 
value of cardiovascular calcifications measured auto-
matically on RT planning CT scans over traditional 
CVD risk factors and breast cancer treatment charac-
teristics to predict (non-)fatal CVD events in patients 
with breast cancer.
Study design and population
For WP 1 and 2, the Bragatston study uses a cohort 
design (figure 1). The cohort will include all patients 
with non-metastatic primary breast cancer treated with 
RT at the University Medical Center Utrecht, Utrecht, 
the Erasmus MC Cancer Institute, Rotterdam and 
the Radboudumc, Nijmegen (n≈16 000), the Nether-
lands. Patients with a prevalent cancer diagnosis will be 
excluded. From these institutions, RT planning CT scans 
and clinical data will be collected starting from the time 
CT RT planning was introduced, which was in 2005 
(University Medical Center Utrecht) and 2006 (Erasmus 
MC Cancer Institute and Radboudumc) until the end of 
2016. The RT planning CT scans that will be collected 
are acquired as part of clinical routine (no contrast 
enhancement, no ECG triggering, 120 kVp, in-plane 
resolution 0.78–1.37 mm, 3.0 mm slice thickness, 3.0 mm 
increment).
For WP 3, a case-cohort study will be conducted.34 The 
case-cohort study will include all cohort members diag-
nosed with a CVD event during follow-up, called here-
after cases. In addition, a random sample will be selected 
at baseline from the cohort to serve as control. To 
increase statistical power, a case-to-control ratio of 1:3 will 
be applied leading to a random sample of approximately 
600 patients. The power gained by including more than 
three controls to one case is little.
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data collection procedures
Automatic calcification quantification
Cardiovascular calcifications will be measured automati-
cally using a calcium scoring algorithm previously devel-
oped in our group.35 The algorithm uses two consecutive 
convolutional neural networks (CNN) to label voxels as 
calcifications in the coronary arteries (left main coronary 
artery, left anterior descending artery, left circumflex 
artery and right coronary artery), as well as calcifications 
in the thoracic aorta and the aortic and mitral valve (leaf-
lets and annulus). The first CNN is used on a large field 
of view to enable learning from contextual spatial infor-
mation. This CNN is able to identify calcified voxels and 
label them according to their anatomical location. The 
second CNN uses a smaller field of view and analyses the 
detailed local texture. This CNN can differentiate the 
true atherosclerotic calcifications among the candidates 
detected by the first CNN (figures 2–5).
The algorithm was initially developed to analyse 
low-dose lung cancer screening CT scans.35 Hence, the 
algorithm has been modified to be able to measure calci-
fications on RT planning CT scans of patients with breast 
cancer. This procedure has been described in detail else-
where.17 The first results show that automatic calcification 
quantification is possible on RT planning CT scans of 
patients with breast cancer. Reproducibility of automat-
ically versus manually measured calcium scores was high 
with linearly weighted kappa values ≥0.84 and intraclass 
correlation coefficients ≥0.94.17 For the current project, 
we will further develop the method to ensure its robustness 
Figure 1 Flow chart of Bragatston study. CDR, National Cause of Death Register; CVD, cardiovascular disease; DHD, 
Dutch Hospital Data; DHR, Dutch Heart Registration; NCR, Netherlands Cancer Registry; PR, Dutch Population Register; RT, 
radiotherapy; UMC, University Medical Center.
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with respect to image acquisition parameters and thereby 
enable its applicability in multicentre settings.
CAC, TAC, AVC and MVC will be expressed in volume 
scores (in mm3). For routine ECG-gated cardiac CT scans, 
CAC is expressed in the Agatston score which also takes 
the calcification density into account.36 The CT scans 
used in this project are ungated and therefore we will 
report CAC as modified Agatston score.37 These modified 
Agatston scores will be calculated by multiplying the calci-
fication area (in mm2) by the density score (1, 130–199 
Hounsfield Units (HU); 2, 200–299 HU; 3, 300–399 
HU; 4, >399 HU) of the area (calcification density) and 
summing the lesion scores, in which a minimal lesion 
definition of 1.5 mm3 will be maintained to eliminate 
noise. Based on these scores, patients will be categorised 
into the Agatston classification consisting of five catego-
ries: 0, 1–10, 11–100, 101–400, >400 Agatston units.
Reference library of manual calcification quantification
Reference standard for calcium scoring will be defined by 
manual calcium scoring. Manual calcium scoring will be 
done in a subset of planning CT scans randomly selected 
per hospital (University Medical Center Utrecht: n=500; 
the Erasmus MC Cancer Institute: n=300; Radboudumc: 
n=200). Calcifications in the coronary arteries, the 
aorta and heart valves will be manually identified and 
labelled. As is standard procedure, three-dimensional 
region growing will be used with a threshold of 130 HU.36 
Manual annotation will be performed by observers who 
will be trained and supervised by a radiologist (PAJ) with 
>10 years of experience in cardiac CT. Subsequently, 
manually annotated calcifications will be quantified to 
determine calcium scores. In line with the automatic calci-
fication quantification, CAC, TAC, AVC and MVC will be 
Figure 2 Example of automatic calcification quantification 
on radiotherapy planning CT scan using our deep learning 
algorithm. Radiotherapy planning CT scan image showing 
calcifications in the left anterior descending artery (in red) and 
left circumflex artery (in green). LAD, left anterior descending 
artery; LCX, left circumflex artery.
Figure 3 Example of automatic calcification quantification 
on radiotherapy planning CT scan using our deep learning 
algorithm. Radiotherapy planning CT scan image showing 
thoracic aorta calcifications (in yellow).
Figure 4 Example of automatic calcification quantification 
on radiotherapy planning CT scan using our deep learning 
algorithm. Radiotherapy planning CT scan image showing 
mitral valve calcifications (in orange) and thoracic aorta 
calcifications (in yellow). MV, mitral valve.
Figure 5 Example of automatic calcification quantification 
on radiotherapy planning CT scan using our deep learning 
algorithm. Radiotherapy planning CT scan image showing 
aortic valve calcifications (in purple) and thoracic aorta 
calcifications (in yellow). AV, aortic valve.
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expressed in volume scores (in mm3). The modified Agat-
ston scores will be calculated as described in the previous 
section. Those reference annotations will be used to train 
the algorithm and to evaluate its performance.
Tumour and treatment characteristics and CVD risk factors
Tumour and breast cancer treatment data will be obtained 
through linkage with the Netherlands Cancer Registry 
(NCR) hosted by the Netherlands Comprehensive Cancer 
Organisation.38 Tumour data variables include tumour 
stage, grade and receptor status and treatment data vari-
ables include type of surgery (breast conserving therapy, 
mastectomy), RT (laterality and radiation fields (if avail-
able)), chemotherapy (yes, no), hormonal therapy (yes, 
no) and immunotherapy (yes, no).
For WP 3, detailed data on breast cancer treatment 
and traditional CVD risk factors present at breast cancer 
diagnosis will be extracted from hospital and general 
practice medical records. The following traditional CVD 
risk factor data will be collected: age, sex, hypertension, 
hypercholesterolaemia, diabetes, smoking and body mass 
index. Regarding hypertension, hypercholesterolaemia, 
diabetes and smoking, a patient will be scored posi-
tive when the risk factor is documented in the hospital 
medical record or reported by the general practitioner by 
means of a questionnaire. Local project members of the 
participating hospitals will perform linkage with the NCR 
and will collect medical record data.
Assessment of outcome
The primary outcome is the incidence of (non-)fatal CVD 
events, which is defined as hospitalisation or death from 
CVD. Death from CVD will be recorded if it is primary 
cause of death, meaning this is the disease that leads to 
death. CVD outcomes will be captured through linkage 
with Dutch Hospital Data (DHD), the Dutch Heart Regis-
tration (DHR), the Dutch Population Register (PR) and 
the National Cause of Death Register (CDR).
DHD collects nationwide medical and administrative 
data for all inpatient and day hospital-care in the Neth-
erlands (ie, Hospital Discharge Register). The DHD 
uses the International Classification of Disease ninth 
revision (ICD-9).39 According to this classification, CVD 
will be categorised as diseases of the circulatory system 
(ICD codes 390–459) and will be further subcategorised 
into the following subcategories: hypertensive disease 
(401–405), ischaemic heart disease (410–414), pericar-
ditis (420), valvular dysfunction (424), cardiomyopathy 
(425), arrhythmia (426–427), heart failure (428) and 
cerebrovascular disease (430–438) and other. Linkage 
with the DHD will be facilitated by Statistics Netherlands 
using the record identification number.40 This number is 
based on a combination of date of birth, sex and postal 
code and is assigned to each resident in the Netherlands.
For a more complete data collection on incident CVD, 
additional linkage with the DHR will be performed.41 The 
DHR collects data on cardiac interventions (eg, percuta-
neous coronary intervention) and cardiothoracic surgery 
(eg, coronary artery bypass surgery, heart valve surgery). 
Linkage will be performed using a combination of identi-
fiers including date of birth, sex and maiden name.
Data on vital status will be obtained from the Dutch 
Population Register (PR). Causes of death will be 
obtained from the CDR maintained by Statistics Nether-
lands. The register contains information on all primary 
and secondary causes of death from all deceased persons 
registered in the Netherlands. Causes of death are clas-
sified according to ICD-10.42 CVD mortality will be cate-
gorised as diseases of the circulatory system (ICD codes 
I00–I99) and will be further subcategorised into the 
following subcategories: hypertensive diseases (I10–I13), 
ischaemic heart diseases (I20–I25), pericarditis (I30–I32), 
valvular dysfunction (I34–I38), cardiomyopathy (I42), 
arrhythmia (I44–I49), heart failure (I50) and cerebro-
vascular diseases (I60–I69) and other. Linkage with the 
PR and CDR will be provided by Statistics Netherlands. 
Linkage will be performed by local project members of 
the participating hospitals. Registries are complete until 
the end of 2016 (DHD and DHR) or 2017 (CDR).
Power calculation
The cohort will consist of approximately 16 000 patients 
with breast cancer (University Medical Center Utrecht: 
n≈8000; Erasmus MC Cancer Institute: n≈5000; 
Radboudumc: n≈3000). A preliminary study was 
conducted within the prospective breast cancer cohort 
Utrecht cohort for Multiple BREast cancer intervention 
studies and Long-term evaLuAtion (UMBRELLA).16 43 In 
total, 561 UMBRELLA patients were included and 24% of 
them had CAC (ie, Agatston score >0).16 By including at 
least 12 000 patients with an average follow-up of 4 years, 
2880 patients will be expected to have CAC. Assuming 
4.5% risk of CVD events after 4 years of follow-up, 130 
CVD events among patients with CAC are expected.44 
In the 9120 patients without CAC, with a CVD risk of 
1.5% after 4 years, 137 CVD events are expected. Based 
on the expected number of at least 200 cases of CVD, a 
maximum of 20 predictor variables can be selected for 
predicting CVD without risk of overfitting.45
Statistical analysis
For WP 1, reliability and agreement will be assessed 
between automatically and manually determined calcium 
scores. Results will be presented for the total sample 
of 1000 manually and automatically assessed planning 
CT scans. In addition, results will be stratified by partici-
pating hospital. Agreement between continuous calcium 
scores will be assessed using Bland-Altman plots and 
between calcium score categories using proportional 
agreement. To determine reliability, intraclass correla-
tion coefficients will be calculated for continuous calcium 
scores. Reliability of calcium categories will be evaluated 
as Cohen’s linearly weighted kappa.
For WP 2, (non-)fatal CVD event rates per 1000 person 
years will be calculated for each calcium score category and 
plotted using Kaplan-Meier survival curves. Differences 
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between categories will be tested with log-rank tests. Cox 
proportional hazard models will be used to examine the 
association between calcium scores and (non-)fatal CVD 
events. Results will be expressed as HRs with their corre-
sponding 95% CIs. Follow-up time will be the underlying 
time variable starting from the date of RT planning CT scan 
and ending at the date of diagnosis of (non-)fatal CVD event 
or censoring. Censored observations will include non-car-
diovascular death, diagnosis of other cancers or end of 
follow-up, whichever came first. Models will be adjusted for 
age at RT planning CT scan and calendar year of RT plan-
ning CT scan. To assess possible effect modification of the 
association between cardiovascular calcifications and CVD 
risk by cardiotoxic chemotherapy, left-sided RT or trastu-
zumab, stratified analysis will be performed. If evidence for 
effect modification will be found, models with and without 
the cross-product term for calcium score and cardiotoxic 
treatment will be compared using a log-likelihood ratio test. 
In order to assess the potential effect of competing events 
precluding the outcome of interest, sensitivity analyses will 
be conducted comprising cumulative incidence analysis 
and competing risk survival analysis as described by Fine 
and Gray.46
For WP 3, in univariable cox regression analysis, we 
will identify which patient characteristics, traditional 
CVD risk factors or breast cancer treatment charac-
teristics are associated with the risk of CVD events. As 
proposed by Prentice, a weighted cox regression model 
will be applied to account for the case-cohort design.34 
Subsequently, a prediction model will be developed 
including patient characteristics, traditional CVD 
risk factors and treatment characteristics. In a second 
prediction model, calcium scores will be added and 
the incremental value of calcium scores in CVD risk 
prediction will be evaluated by comparing discrimina-
tion (c-statistics) and reclassification (net reclassifica-
tion index). To take into account the potential effect 
of missing data, a sensitivity analysis will be conducted 
imputing missing values of traditional CVD risk factor 
and breast cancer treatment variables using multiple 
imputation.47
Patient and public involvement
We will conduct a survey among 100 UMBRELLA 
patients to explore their preferences regarding disclo-
sure of calcium scores and corresponding CVD risk. 
Themes that will be included in the questionnaire are 
patient’s knowledge about CVD risk following a breast 
cancer diagnosis, the patient’s wish to be informed 
about CVD risk and preferences on way of disclosure of 
CVD risk. The survey will be developed in collaboration 
with the Dutch Patient Advocacy Group, a joint initia-
tive from the Dutch Breast Cancer Research Group 
and the Dutch Breast Cancer Association.48 49 We will 
inform patients with breast cancer about the results 
of this project by means of newsletters and presenta-
tions at patient conferences, for example, at the annual 
UMBRELLA patient conference.
Timeline
Data collection started in January 2017 and we expect 
to complete data collection in December 2019. The esti-
mated end date of the study is March 2020.
Ethics and dissemination
The Institutional Review Boards decided that the Medical 
Research Involving Human Subjects Act does not apply 
to the study. The requirement for informed consent 
was waived in accordance with the Code of Conduct for 
Medical Research developed by the Federation of Medical 
Scientific Societies.50 All data, with the exception of data 
provided by Statistics Netherlands, will be stored centrally 
at the University Medical Center Utrecht. This dataset will 
be sent to Statistics Netherlands for additional linkage. 
Analyses will be performed in a secure environment of 
Statistics Netherlands. The dataset will be anonymised by 
Statistics Netherlands. The results of the Bragatston study 
will be published in international peer-reviewed journals 
and presented at scientific conferences.
dISCuSSIon
The Dutch Bragatston study has been set up to optimise 
and validate an automated deep learning algorithm for 
the identification of patients with breast cancer at high 
risk of CVD based on the presence of cardiovascular calci-
fications on RT planning CT. Most breast cancer treatment 
guidelines and survival prediction tools mainly focus on 
tumour characteristics while other patient characteristics 
are hardly taken into account. In the era of personalised 
medicine, given the high burden of CVD in patients with 
breast cancer it is critical to incorporate patient CVD risk 
factors in treatment decisions to find an optimal balance 
between cancer control and cardiotoxicity. Automated 
measurement of cardiovascular calcifications on RT plan-
ning CT scans may be an elegant solution, because RT 
planning CT scans are readily available imaging data and 
therefore there is no additional (radiation exposure) 
harm to patients and only a minimal financial burden to 
society when calcium scores are measured on these scans.
If we find that cardiovascular calcifications measured 
on RT planning CT scans are predictors of CVD risk, 
the next step will be to investigate how to act on this 
information and how to disclose this information to 
the patient. The dilemma of disclosing calcium scores 
and corresponding CVD risk lies in the fact that there 
is no evidence yet regarding effective risk reducing 
interventions. Thus far, no randomised trials have been 
conducted on the effectiveness of calcium score-based 
treatment strategies with CVD morbidity and mortality 
reduction as outcome measure.51 The Risk Or Benefit IN 
Screening for CArdiovascular diseases (ROBINSCA) trial 
is the first ongoing randomised controlled trial investi-
gating the value of CAC imaging followed by preventive 
treatment in reducing coronary heart disease-related 
mortality and morbidity.52 In the intervention arm, partic-
ipants with a CAC Agatston score >100 will be treated with 
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statins and ACE inhibitors, independent of their blood 
cholesterol level and blood pressure value. The results 
of the ROBINSCA trial might provide important insights 
potentially relevant for patients with breast cancer with 
moderate or high CAC score.
The importance of our study lies in the possibility to 
introduce targeted preventive interventions to reduce 
treatment-related CVD. Those include minimisation of 
the mean RT heart dose, for example, by application of 
volumetric modulated arc therapy instead of the stan-
dard three-dimensional conformal radiation therapy.53 
Furthermore, chemotherapy-induced cardiotoxicity 
may be reduced by switching to less harmful regimens, 
for example, an anthracycline-free regime consisting 
of docetaxel, carboplatin and trastuzumab has been 
described for human epidermal growth factor receptor 
2-positive breast cancer as a more heart-friendly alterna-
tive to the standard regimen.19 21 27 Another strategy is to 
screen for and treat modifiable cardiovascular risk factors 
like high blood pressure, diabetes mellitus and high 
cholesterol levels.18–20 Additionally, increased awareness 
needs to be generated among physicians to identify and 
refer patients with breast cancer at high risk for CVD to 
a cardio-oncologist. Cardio-oncology is a new upcoming 
discipline focused on cardiovascular care for patients 
with cancer which comprises CVD risk stratification, close 
monitoring during and after cancer treatment by means 
of imaging techniques or circulating biomarkers and 
management of a possible CVD event.18 20 27
In conclusion, over the last two decades, advances in 
breast cancer treatments has led to improved survival 
rates. However, these treatments can increase the risk of 
CVD. To optimise the individual benefit and risk evalu-
ation of treatment options, we propose to evaluate the 
inclusion of information on patient CVD risk. Automated 
measurement of cardiovascular calcifications on routinely 
obtained RT planning CT scans may be an inexpensive, 
fast and accurate solution. The Bragatston study will 
determine the correlation between those RT planning CT 
detected cardiovascular calcifications and the occurrence 
of CVD events.
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